Cybin to move U.S. stock listing to Nasdaq from NYSE American (CYBN:NYSE) Cybin moves its U.S. stock listing from NYSE American to Nasdaq in January 2026, rebranding as “HELP.” Discover what this means for investors—read now!

Cybin to move U.S. stock listing to Nasdaq from NYSE American

#cybn

Origin | Interest | Match

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq Cybin Inc., a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market from the NYSE American LLC. The Company is currently developing...

#CYBN Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

www.stocktitan.net/news/CYBN/cybin-to-trans...

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights Cybin Inc., a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its second quarter ended September 30, 2025, and recent business highlights. Dosing is currently ongoing in the first...

#CYBN Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

www.stocktitan.net/news/CYBN/cybin-reports-...

#CYBN Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

www.stocktitan.net/news/CYBN/cybin-to-annou...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OKLO 74% OTM
2. #HIMS 58% OTM
3. #NTLA 52% OTM
4. #CYBN 39% OTM
5. #BYND 38% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OKLO, #HIMS, #CYBN, #CRWV, #VTYX

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OKLO, #CYBN, #KC, #CIFR, #SBET

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OKLO 74% OTM
2. #NTLA 52% OTM
3. #BYND 44% OTM
4. #CYBN 39% OTM
5. #CIFR 32% OTM

#OptionFlow #OptionsTrading #Trading

Cybin Announces $175 Million Registered Direct Offering Cybin (NYSE American: CYBN) announced a registered direct offering of 22,277,750 common shares and pre-funded warrant equivalents at US$6.51 per share/pre-funded warrant for aggregate gross proceeds of US$175,009,911.45. Each security includes 0.35 warrant exercisable at US$8.14 until June 30, 2027 or earlier on specified trial or market triggers. Proceeds are intended to repay outstanding High Trail convertible debentures in full, advance CYB003, CYB004, and CYB005 clinical programs, and for working capital. The offering is led by Jefferies, TD Cowen, and Cantor and is expected to close on October 31, 2025, subject to exchange approvals and customary conditions.

#CYBN Cybin Announces $175 Million Registered Direct Offering

www.stocktitan.net/news/CYBN/cybin-announce...

Pomerantz Law Firm Launches Investigation for Cybin Inc. Investors Amid Allegations Pomerantz LLP is investigating allegations against Cybin Inc. (CYBN) for possible claims of securities fraud. Investors are urged to contact the firm for details.

Pomerantz Law Firm Launches Investigation for Cybin Inc. Investors Amid Allegations #USA #New_York #Pomerantz_LLP #Cybin_Inc #CYBN

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones Cybin (NYSE American:CYBN) has provided updates on its neuropsychiatry platform and clinical milestones. The company has completed enrollment of 36 participants in its Phase 2 study of CYB004 (deuterated DMT) for Generalized Anxiety Disorder, with topline data expected in Q1 2026.The company is advancing CYB003, its deuterated psilocin analog, in Phase 3 studies for major depressive disorder (MDD). The APPROACH study aims to enroll 220 patients across 45 U.S. clinical sites, while the EMBRACE study targeting 330 participants is set to begin in Q4 2025.Cybin boasts a robust intellectual property portfolio with 100+ granted patents and 250+ pending applications. The company has partnered with Thermo Fisher Scientific for U.S.-based commercial-scale manufacturing and Osmind for commercial preparation across 800+ psychiatry clinics.

#CYBN Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

www.stocktitan.net/news/CYBN/cybin-highligh...

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder Cybin (NYSE:CYBN) has received Australian approval for EMBRACE, its second pivotal Phase 3 study evaluating CYB003 for Major Depressive Disorder (MDD) treatment. The study will enroll 330 participants across approximately 60 clinical sites in the US, Europe, and Australia.The EMBRACE study is part of the larger PARADIGM program and follows recent approvals in Ireland, Poland, Greece, and the UK. The trial will feature three arms: high dose (16mg), mid-dose (8mg), and placebo, with participants receiving two doses three weeks apart. Previous Phase 2 results showed impressive outcomes, with 71% of participants achieving remission and 100% responding to treatment at 12 months after two 16mg doses.CYB003, which has received FDA Breakthrough Therapy Designation, will be studied in patients with moderate to severe MDD who show inadequate response to current antidepressants.

#CYBN Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

www.stocktitan.net/news/CYBN/cybin-receives...

93% Shareholder Support: Biotech Cybin Confirms New 6-Member Board Structure at Annual Meeting Neuropsychiatry company Cybin's shareholders approved six directors with up to 86% support, appointed Zeifmans LLP as auditor with 99.5% approval. 48.92% of shares represented.

#CYBN Cybin Announces Results of Annual Meeting of Shareholders

www.stocktitan.net/news/CYBN/cybin-announce...

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results Cybin (NYSE American:CYBN) reported significant progress in its Q1 FY2026 and key milestones for its neuropsychiatry programs. The company received European and UK MHRA approval for EMBRACE, its second Phase 3 study of CYB003 for Major Depressive Disorder (MDD), which will enroll 330 participants across 60 clinical sites globally.The company secured US$50 million in convertible debentures and reported cash reserves of US$118.7 million as of June 30, 2025. The PARADIGM program, including APPROACH and EMBRACE studies, will evaluate CYB003 in approximately 550 participants. Additionally, Cybin expects to complete patient enrollment for its CYB004 Phase 2 study in General Anxiety Disorder in August 2025.

#CYBN Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

www.stocktitan.net/news/CYBN/cybin-reports-...

Breakthrough Depression Drug Shows 71% Remission Rate as Phase 3 Trial Expands to Europe European regulators greenlight Phase 3 EMBRACE trial for novel depression treatment following impressive 71% remission rate in Phase 2. See full trial details.

#CYBN Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

www.stocktitan.net/news/CYBN/cybin-receives...

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder Cybin (NYSE:CYBN) has received UK MHRA approval to commence EMBRACE, the second pivotal Phase 3 study within its PARADIGM program evaluating CYB003, a deuterated psilocin analog for Major Depressive Disorder (MDD).The EMBRACE study will enroll 330 participants across approximately 60 clinical sites in the U.S., Europe, and Australia. The PARADIGM program, which includes APPROACH and EMBRACE studies plus EXTEND long-term extension, targets a total enrollment of 550 participants. The trial will evaluate two doses (16mg and 8mg) of CYB003 against placebo, administered three weeks apart.Notably, CYB003 has received Breakthrough Therapy Designation from the FDA. The company highlighted encouraging market signals, referencing esketamine's commercial success with $414 million in worldwide Q2 2025 sales, representing 61.1% U.S. growth year-over-year.

#CYBN Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

www.stocktitan.net/news/CYBN/cybin-receives...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OPEN, #CYBN, #SVM, #VEEV, #MUX

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OPEN 3.7x
2. #CYBN 3.1x
3. #SVM 2.9x
4. #VEEV 2.9x
5. #MUX 2.9x

#OptionFlow #OptionsTrading #Trading

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures Cybin (NYSE American: CYBN) has announced a significant financing agreement with High Trail Special Situations LLC for up to US$500 million in convertible debentures. The initial tranche of US$50 million was completed on June 30, 2025, with the remaining US$450 million to be determined at a future date upon mutual agreement.The convertible debentures feature a two-year term with a 5.5% annual interest rate, prepaid at closing. The conversion price includes a potential 30% premium, calculated as the lower of 130% of the VWAP prior to issuance or the VWAP during the five trading days before conversion.The funding will accelerate Cybin's clinical programs, particularly CYB003, which showed a 71% remission rate in major depressive disorder at 12 months, and CYB004 for generalized anxiety disorder. The company plans to use the proceeds for working capital and general corporate purposes, supporting its Phase 3 PARADIGM program and ongoing clinical trials.

#CYBN REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

www.stocktitan.net/news/CYBN/repeat-cybin-a...

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights Cybin Inc. (NYSE American:CYBN), a clinical-stage neuropsychiatry company, has reported its fiscal year 2025 financial results and business updates. The company is advancing its Phase 3 CYB003 PARADIGM program, which includes two 12-week studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), targeting approximately 550 patients total.Key clinical highlights include impressive Phase 2 results for CYB003 in major depressive disorder (MDD), where 100% of participants receiving two 16mg doses were responders and 71% achieved remission. The company is also progressing with its CYB004 Phase 2 study for generalized anxiety disorder, expected to complete around mid-2025.Financially, Cybin reported cash reserves of C$135 million as of March 31, 2025. The company recorded a net loss of C$113 million for the fiscal year, compared to C$78 million in the previous year. Strategic partnerships have been established with Osmind for commercial preparations and Thermo Fisher Scientific for U.S.-based manufacturing.

#CYBN Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/CYBN/cybin-reports-...

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures Cybin (NYSE American: CYBN) has entered into a significant financing agreement with High Trail Special Situations LLC for up to US$500 million in convertible debentures. The initial tranche of US$50 million was completed on June 30, 2025, with the remaining US$450 million to be determined at a future date upon mutual agreement.The convertible debentures feature a two-year term with a 5.5% annual interest rate, pre-paid at closing. The conversion price includes a potential 30% premium and is based on the lower of 130% of the pre-issuance VWAP or the 5-day VWAP prior to conversion.The funding will accelerate Cybin's clinical programs, particularly CYB003, which showed a 71% remission rate in major depressive disorder at 12 months, and CYB004 for generalized anxiety disorder. The company's pipeline includes a multinational Phase 3 PARADIGM program for CYB003 and an ongoing Phase 2 GAD study for CYB004. [ "Secured substantial financing of up to US$500 million through convertible debentures", "CYB003 demonstrated exceptional 71% remission rate in depression treatment with 12-month durability", "Received FDA Breakthrough Therapy Designation for CYB003", "Strong intellectual property portfolio with 90+ issued patents and 230+ pending applications", "Initial US$50 million funding completed with flexible terms for additional US$450 million", "Phase 3 PARADIGM program advancing with multiple near-term catalysts" ]

#CYBN Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

www.stocktitan.net/news/CYBN/cybin-announce...

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics Cybin Inc. (NYSE:CYBN) has provided a corporate update highlighting significant progress in its psychedelic therapeutics development. The company is currently conducting Phase 3 PARADIGM trials for CYB003 in Major Depressive Disorder, targeting approximately 550 participants across three studies. Key partnerships have been established with Osmind for commercialization preparation, leveraging an 800-clinic network, and Thermo Fisher Scientific for U.S.-based manufacturing. The company has strengthened its intellectual property portfolio with two additional U.S. patents for CYB003 and CYB004 programs, bringing the total to over 90 granted patents. Notably, positive regulatory signals from U.S. agencies, including FDA Commissioner Dr. Makary's commitment to expedited review of psychedelics and increasing bipartisan support, suggest an improving regulatory environment for psychedelic medicine.

#CYBN Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

www.stocktitan.net/news/CYBN/cybin-provides...

Cybin Secures New U.S. Patent for DMT-Based Anxiety Treatment Program, Bolstering Phase 2 Clinical Development Cybin Inc. (CYBN), a company advancing next-generation mental health treatments using psychedelics, has been granted a new U.S. patent supporting its CYB004 pro

#CYBN strengthens its psychedelic therapeutics pipeline with a newly granted U.S. patent for its DMT-based anxiety treatment program — a major step forward as it advances into Phase 2 clinical development.
#CybinInc
prismmarketview.com/cybin-secure...

Cybin Secures 20-Year Patent Protection for Revolutionary Anxiety Treatment in Phase 2 Trials Novel DMT-based anxiety treatment secures patent protection until 2040. Innovative intramuscular delivery method shows promise in ongoing Phase 2 trials. Learn more.

#CYBN Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

www.stocktitan.net/news/CYBN/cybin-announce...

Cybin Welcomes FDA’s Embrace of Psychedelic Therapeutics as a Mental Health Priority FDA Commissioner Calls for Innovation in Mental Health Treatments Cybin Inc. (NYSE: CYBN), a clinical-stage neuropsychiatry company developing next-generatio

#CYBN celebrates FDA’s focus on psychedelic therapeutics as a mental health priority! Promising advancements in treatments for depression and anxiety are on the horizon.
#CybinInc
#Psychedelics #MentalHealth #Biotech prismmarketview.com/cybin-welcom...

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics The FDA Commissioner Dr. Martin Makary has identified psychedelic drug development as a top agency priority, emphasizing the need to accelerate research for mental health treatments. This stance particularly benefits Cybin Inc. (CYBN), whose deuterated psilocin program CYB003 has received FDA Breakthrough Therapy Designation for major depressive disorder (MDD) treatment. The company's Phase 2 results showed remarkable efficacy, with 100% response rate and 71% remission rate in participants receiving two 16mg doses. Cybin is currently conducting its Phase 3 PARADIGM program, which includes two 12-week studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND). Additionally, their CYB004 deuterated DMT program is progressing in Phase 2 trials for generalized anxiety disorder, expected to complete by mid-2025.

#CYBN Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

www.stocktitan.net/news/CYBN/cybin-applauds...

Cybin's Breakthrough Depression Drug Achieves 100% Response Rate, Partners With Thermo Fisher for Phase 3 Production FDA Breakthrough-designated CYB003 enters U.S. manufacturing phase after achieving 100% response rate in Phase 2 depression trials. See commercial timeline.

#CYBN Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

www.stocktitan.net/news/CYBN/cybin-engages-...

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder Cybin (NYSE:CYBN) has secured a new U.S. patent (12,291,499) for its CYB003 program, which is currently in Phase 3 development for Major Depressive Disorder (MDD). The patent, providing exclusivity until 2041, covers pharmaceutical compositions and oral dosage forms within the company's proprietary deuterated psilocin analog program.The company's intellectual property portfolio now includes over 80 granted patents and 230+ pending applications. Cybin is actively conducting two Phase 3 studies: the ongoing APPROACH study for CYB003 as an adjunctive treatment for MDD, and the upcoming EMBRACE study, scheduled to begin in mid-2025. [ "New U.S. patent granted with exclusivity until 2041, strengthening IP protection for CYB003", "Robust intellectual property portfolio with 80+ granted patents and 230+ pending applications", "Two Phase 3 clinical trials advancing: APPROACH (ongoing) and EMBRACE (starting mid-2025)" ]

#CYBN Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

www.stocktitan.net/news/CYBN/cybin-announce...

Breakthrough Depression Treatment Achieves 71% Remission Rate as Cybin Accelerates Phase 3 Trial Network New clinical partnerships boost Cybin's Phase 3 depression drug trial to 18 sites. Follows groundbreaking 71% remission rate in Phase 2. See expansion details.

#CYBN Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

www.stocktitan.net/news/CYBN/cybin-announce...